N-Zyme Biomedical raises $4.6M Series A to advance pepsin inhibitor for reflux disease
What's the deal? N-Zyme Biomedical has closed a US$4.6 million Series A round to fund Phase 2 clinical programs for its pepsin inhibitor platform targeting reflux disease. The round drew a mix of healthcare professionals, entrepreneurs, a venture capital group, and strategic investors.
What's the endgame? The company is developing a therapy that inhibits pepsin, the digestive enzyme increasingly linked to tissue damage and persistent symptoms in reflux disease. That differs from conventional treatments, which mainly reduce gastric acid.
Where the money goes: Proceeds will fund the ongoing Phase 2 study of its lead candidate for laryngopharyngeal reflux (LPR) and planned Phase 2 work in proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD). Funds also cover regulatory, manufacturing, and business development activities.
Why now? The raise follows what N-Zyme calls a period of momentum, including the launch of its LPR clinical program and continued expansion of its intellectual property portfolio.
“Closing our Series A financing is more than a funding milestone—it's an important validation of our science, our strategy, and our team's commitment to transforming the treatment of reflux disease,” said Franco VigileDealroom has a profile for this one. Try Dealroom →, co-founder and chief executive officer.
The signal: By targeting pepsin rather than acid production, N-Zyme is betting on a different mechanism for patients who don't respond to standard PPI therapy — a segment the company frames as a large unmet need. The Phase 2 results will test whether that scientific bet holds.
Read more: AP News
Image credit: foteih
